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Background
Lynch syndrome (LS) is a hereditary cancer condition
associated with germline mutations in the mismatch
repair genes MLH1, MSH2, MSH6 and PMS2. This
condition has been traditionally described in terms of
an increased risk for early-onset colorectal and endo-
metrial cancers. Individuals with LS additionally have
an increased risk to develop other cancers including
ovarian, gastric, urinary tract, hepatobiliary tract, small
bowel, brain, and skin cancers. The preferred method
of genetic testing for LS is to initially perform microsa-
tellite instability (MSI) analysis and/or immunohisto-
chemistry (IHC) staining as a test on the tumor tissue
of an affected individual. If abnormal, this testing
would indicate that a germline mismatch repair gene
mutation is more likely to explain the cancer and, if
IHC is performed, may also indicate which gene to test
first via molecular analysis. MSI/IHC has been more
widely validated for colon and endometrial cancers as
opposed to other cancers associated with this
condition.
Case report
We report a 66-year-old male patient with past history
of multiple cancers including colon and kidney cancer,
and recently diagnosed with jejunal adenocarcinoma.
Family history of Lynch-associated cancers included
brain, gastric and endometrial cancer, noted to have
later ages of onset (Figure 1). The patient had MSI/IHC
testing performed on his small bowel cancer and this
was reported as abnormal with MSI-high in 5/5 markers
and absent MSH6 staining (Figure 2). Subsequent blood
draw revealed the presence of a pathogenic MSH6 gene
mutation, 3202C>T (R1068X).
Conclusion
As we learn more about the etiology and cancer
risks associated with LS, the expanding phenotypic spec-
trum of this condition and its genotype-phenotype cor-
relations are being elucidated. Specifically, MSH6
mutations have been associated with a higher cumula-
tive risk for endometrial cancer with a later age of onset
as compared to other mismatch repair gene mutations
[1-5], and cancers other than colon and endometrial
may account for as much as 50% of cancer reported
with MSH6 mutations [6]. Clarifying the efficacy of
MSI/IHC in other extra-colonic cancers associated with
LS is important, since certain cases of LS are likely to
present in a clinically atypical manner.
This case illustrates the phenotypic variability of this
condition, and complications it may present in evalua-
tion for diagnosis and appropriate surveillance and man-
agement recommendations. It also suggests that testing
by MSI/IHC may be very feasible as a first step in LS
identification using tumor tissue beyond what has been
traditionally reported in the literature.
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reproduction in any medium, provided the original work is properly cited.Figure 2 Immunihistochemistry on jejunal adenocarcinoma demonstrating loss of MSH6 protein expression. Immunohistochemical staining of
patient small bowel adenocarcinoma tissue demonstrating normal protein expression for MLH1 (a), MSH2 (b), and PMS2 (d), and abnormal lack
of expression for MSH6 (c). Note: Internal control tissue was evaluated and revealed positive staining while tumor cells were negative.
Figure 1 Pedigree of Lynch syndrome family with MSH6 mutation.
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